Editas Medicine, Inc.

NasdaqGS:EDIT Stock Report

Market Cap: US$108.1m

Editas Medicine Valuation

Is EDIT undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of EDIT when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate EDIT's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate EDIT's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for EDIT?

Key metric: As EDIT is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for EDIT. This is calculated by dividing EDIT's market cap by their current revenue.
What is EDIT's PS Ratio?
PS Ratio1.7x
SalesUS$61.76m
Market CapUS$108.14m

Price to Sales Ratio vs Peers

How does EDIT's PS Ratio compare to its peers?

The above table shows the PS ratio for EDIT vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average9.1x
TLSI TriSalus Life Sciences
4.7x33.4%US$123.5m
MDXH MDxHealth
1.2x15.4%US$106.9m
YMTX Yumanity Therapeutics
29.7xn/aUS$143.6m
STRO Sutro Biopharma
1x17.7%US$155.0m
EDIT Editas Medicine
1.7x0.7%US$108.1m

Price-To-Sales vs Peers: EDIT is good value based on its Price-To-Sales Ratio (1.7x) compared to the peer average (2.1x).

Price to Sales Ratio vs Industry

How does EDIT's PS Ratio compare vs other companies in the US Biotechs Industry?

136 CompaniesPrice / SalesEstimated GrowthMarket Cap
Industry Avg.9.8x20.8%
EDIT Editas Medicine
 1.7x0.7%US$108.14m
BIIB Biogen
2.3x1.3%US$21.34b
MRNA Moderna
3x5.8%US$15.16b
EDIT 1.7xIndustry Avg. 9.8xNo. of Companies136PS01632486480+
136 CompaniesEstimated GrowthMarket Cap
Industry Avg.9.8x27.6%
EDIT Editas Medicine
 1.7x7.7%US$108.14m
No more companies

Price-To-Sales vs Industry: EDIT is good value based on its Price-To-Sales Ratio (1.7x) compared to the US Biotechs industry average (9.8x).

Price to Sales Ratio vs Fair Ratio

What is EDIT's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

EDIT PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio1.7x
Fair PS Ratio0.2x

Price-To-Sales vs Fair Ratio: EDIT is expensive based on its Price-To-Sales Ratio (1.7x) compared to the estimated Fair Price-To-Sales Ratio (0.2x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst EDIT forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$1.25
US$3.67
+193.3%
56.0%US$8.00US$1.00n/a9
Dec ’25US$2.24
US$8.15
+264.0%
46.6%US$15.00US$1.00n/a13
Nov ’25US$2.91
US$11.63
+299.5%
43.8%US$23.00US$3.00n/a16
Oct ’25US$3.27
US$13.50
+312.8%
44.4%US$27.00US$7.00n/a16
Sep ’25US$3.74
US$13.53
+261.9%
45.7%US$27.00US$7.00n/a15
Aug ’25US$5.14
US$14.27
+177.6%
42.9%US$27.00US$7.00n/a15
Jul ’25US$4.61
US$14.47
+213.8%
41.2%US$27.00US$7.00n/a15
Jun ’25US$5.20
US$14.60
+180.8%
40.7%US$27.00US$7.00n/a15
May ’25US$5.47
US$15.40
+181.5%
35.0%US$27.00US$7.00n/a15
Apr ’25US$7.28
US$15.40
+111.5%
35.0%US$27.00US$7.00n/a15
Mar ’25US$10.53
US$15.40
+46.2%
35.0%US$27.00US$7.00n/a15
Feb ’25US$7.22
US$15.21
+110.7%
37.7%US$27.00US$7.00n/a14
Jan ’25US$10.13
US$14.67
+44.8%
40.0%US$27.00US$7.00n/a15
Dec ’24US$10.77
US$13.53
+25.7%
44.1%US$27.00US$7.00US$2.2415
Nov ’24US$6.90
US$13.53
+96.1%
43.7%US$30.00US$7.00US$2.9115
Oct ’24US$7.80
US$13.63
+74.7%
42.0%US$30.00US$7.00US$3.2716
Sep ’24US$9.08
US$13.18
+45.1%
42.4%US$30.00US$7.00US$3.7417
Aug ’24US$8.65
US$13.41
+55.0%
43.4%US$30.00US$7.00US$5.1417
Jul ’24US$8.23
US$13.41
+63.0%
43.4%US$30.00US$7.00US$4.6117
Jun ’24US$9.55
US$12.71
+33.0%
47.0%US$30.00US$7.00US$5.2017
May ’24US$8.30
US$12.71
+53.1%
47.6%US$30.00US$7.00US$5.4717
Apr ’24US$7.25
US$13.06
+80.1%
45.7%US$30.00US$7.00US$7.2817
Mar ’24US$8.72
US$13.06
+49.8%
45.7%US$30.00US$7.00US$10.5317
Feb ’24US$10.41
US$14.24
+36.7%
59.1%US$36.00US$7.00US$7.2217
Jan ’24US$8.87
US$16.38
+84.6%
74.1%US$50.00US$7.00US$10.1316
Dec ’23US$10.06
US$17.27
+71.6%
70.8%US$50.00US$7.00US$10.7715

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 14:30
End of Day Share Price 2024/12/23 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Editas Medicine, Inc. is covered by 34 analysts. 17 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jack AllenBaird
Joel BeattyBaird
Huidong WangBarclays